Lost password ?
Gulf Pharmaceutical
Modest 2023 results despite a better-than-expected Q4
- "Julphar has reported a revenue rise of 1.4% in 2023 to reach AED1,638m. The net loss has widened to AED103.1m, compared to a loss of AED31.7m in 2022. "
Executive summary
Conflicts of Interest
Pages 40
Language English
Publish on March 4, 2024
€ 500
VAT Exl.
You may also be interested by these reports :
FIND A REPORT
SIMPLE, TO THE POINT IDEA GENERATION
Each company is researched in depth using a structured, robust and transparent process. Valuations are disciplined and dispassionate.
AlphaMena allows you to compare stocks along a wide range of parameters be it by sector, by geography or an array of investment themes.
Our reports include actuarial as well as off balance-sheet data and governance metrics.
Priority is given to idea generation through quick, to the point, answers by means of browsing from one idea to the next.